drugset / Trial / NCT00036816

Vaccine Therapy in Treating Patients With Melanoma of the Eye

NCT00036816

RandomizedTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells and decrease the recurrence of melanoma of the eye. PURPOSE: Randomized phase III trial to determine the effectiveness of vaccine therapy in treating patients who are at high risk for recurrent melanoma of the eye.

Timeline

Start
2002-02
Primary completion
2003-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject MART-1 antigen Vaccine Subcutaneous
Subject NA17-A Vaccine Subcutaneous
Subject gp100 antigen Peptide Subcutaneous
Subject tyrosinase Peptide Subcutaneous

Indications